Press Releases

 
Press Releases
  Date Title and Summary View
Nov 6, 2017
HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its financial results for the quarter and nine months ended September 30, 2017. Third Quarter 2017 Financial Highlights Total revenues of $2.99 billion, down 2% compared to the prior year period North America ...
Nov 1, 2017
DUBLIN, Ireland, HERTFORDSHIRE, England and PITTSBURGH, Nov. 1, 2017 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced the presentation of additional positive efficacy data from the three-month, pivotal Phase 3 studies of revefenacin (TD-4208) at the 2017 ...
Oct 31, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 31, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) provided the following statement in response to the announcement of proposed amendments to the civil complaint by various states' attorneys general in multi-district litigation pending in the U.S. District Court for the Eastern District of Pennsylvan...
Oct 27, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 27, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced its EpiPen4Schools® program has surpassed the one millionth epinephrine auto-injector donation through the program and that presented data at the American College of Allergy, Asthma and Immunology (ACAAI) 2017 Annual Scientific M...
Oct 26, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 26, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United Kingdom's High Court of Justice has issued a decision in favor of Mylan and its European partner Synthon, finding all claims of Teva's patent EP (UK) 2 949 335 (EP 335) relating to Copaxone® 40 mg/mL invalid based...
Oct 17, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 17, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Monday, Nov. 6, 2017, at 10:30 a.m. ET, to review the company's financial results for the third quarter ended Sept. 30, 2017. Mylan will release its financial results on Nov. 6,...
Oct 16, 2017
HERTFORDSHIRE, England, and PITTSBURGH, Oct. 16, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that the United States District Court for the Eastern District of Texas has issued a 135-page decision finding all asserted claims of the patents relating to Restasis® invalid based on obviousness. The Court, recognizing that Al...
Oct 5, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that partner, Synthon, received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg/mL, a therapeutically equivalent generic version of Teva's Copaxone® 40 mg/mL, indicated for the treatment of patien...
Oct 5, 2017
HERTFORDSHIRE, England and PITTSBURGH, Oct. 5, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Moxifloxacin Hydrochloride in 0.8% Sodium Chloride Injection, 400 mg/250 mL (1.6 mg/mL) in 250 mL single-dose flexible bags, the first AP-rated generic version of Bayer's Avelox®. The product is being marketed a...
Oct 4, 2017
HERTFORDSHIRE, England, and PITTSBURGH, Oct. 4, 2017 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the company has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated substitutable generic version of Teva's Copaxone® 40 mg/mL, as well as Glatiramer Acetate ...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase